ERBB2 and non-small cell lung carcinoma: Subsequently, the DESTINY-Lung 02 trial (NCT04644237) (16), a blinded phase II study, compared the efficacy and safety of DS-8201 at doses of 5.4 mg/kg and 6.4 mg/kg in 152 platinum-treated patients with HER2-mutant NSCLC, more than 70% of whom had received prior anti-PD-(L)1 therapy.